Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT-3500
- Development stage
- Preclinical
- Lead developer
- Circadian Therapeutics
- Modality
- Small Molecules
01
Overview
CT-3500 is an investigational small molecule therapeutic being developed by Circadian Therapeutics, a biotechnology company spun out from the University of Oxford. The program is aimed at treating metabolic disorders, specifically obesity and non-alcoholic steatohepatitis (NASH), by modulating the body's internal circadian clock. Circadian disruption is a known driver of metabolic dysfunction, and CT-3500 is designed to restore or optimize these rhythms to improve metabolic outcomes. As of early 2024, the specific molecular target of CT-3500 has not been publicly disclosed, and the candidate is in the early stages of development.
Beyond the preview
Go deeper on CT-3500.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT-3500.